Fig. 3: Forest plot showing HR of belotecan relative to topotecan for OS in different subgroups. | British Journal of Cancer

Fig. 3: Forest plot showing HR of belotecan relative to topotecan for OS in different subgroups.

From: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

Fig. 3

HR (95% CI) < 1 indicates significantly longer survival in the belotecan group than in the topotecan group. Dagger indicates that patients with symptomatic brain metastasis within 3 months prior to study entry were excluded from this study. HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, LD limited-stage disease, ED extensive-stage disease, RDI relative dose intensity.

Back to article page